Wells Fargo Maintains Equal-Weight on Kymera Therapeutics, Raises Price Target to $38
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Derek Archila maintains an Equal-Weight rating on Kymera Therapeutics (NASDAQ:KYMR) and raises the price target from $30 to $38.
August 12, 2024 | 5:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo analyst Derek Archila maintains an Equal-Weight rating on Kymera Therapeutics and raises the price target from $30 to $38.
The raised price target from $30 to $38 by a reputable analyst at Wells Fargo is a positive signal for investors, indicating increased confidence in the company's future performance. This is likely to have a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100